Bio-Path stock: buy or sell?

BPTH stock price: $5.02 -1.18% At close on May 14th, 2020

Updated on:
May 14th, 2020


Shares of Bio-Path closed today at $5.02 and slightly fell a bad -1.18%.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States.

Should I buy Bio-Path stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Bio-Path stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean BPTH will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Bio-Path stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for BPTH stock for the last month.

Bio-Path stock analysis

Daily outlook

Shares of Bio-Path slightly fell a bad -1.18% and closed at $5.02.

Shares of Bio-Path closed today at $5.02 and slightly fell a bad -1.18%. Since price and SMA50d lines crossed up on Friday, BPTH climbed $0.33 (7.04%).

BPTH stock chart (daily)

Weekly outlook

After boosting a great 5.27% in a week last week, Bio-Path closed this week at $5.02 and raised a beatiful 1.83%. Late April BPTH plunged a dreadful -22.70% in just one week.

If you observe the weekly chart, price is in a simple uptrend, tested $4.35 level and now climbing back aiming its last top at $6.16. Early September BPTH price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

BPTH stock chart (weekly)

Bio-Path stock price history

Bio-Path stock went public on March 15th, 2010 with a price of $100.001. Since then, BPTH stock declined a -95.00%, with a yearly average of -9.50%.

1: Adjusted price after possible price splits or reverse-splits.

Bio-Path stock historical price chart

BPTH stock reached 52-week highs at $19.00, and all-time highs 2014-01-03 with a price of 1050.

Bio-Path stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we have not found any price forecast for Bio-Path stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, when Bio-Path posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
BPTH earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2017, Bio-Path annual sales boosted an amazing 184.62% to $0.04 million dollars from $0.01 marked in 2016. Similarly, its income margin (compared to sales) skyrocketed to -18,981.08%, that is $-7.02 million.

BPTH annual Sales and Income evolution
2016$0.01 M-$-6.75 M-51923.1%-
2017$0.04 M184.62%$-7.02 M-18981.1%4.04%

Quarterly financial results

Reported quarter earnings marked $-1.91 M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Bio-Path sales marked a bloodcurdling loss and plunged a -100.00%. Looking back to recent quarterly results, Bio-Path posted 4 positive quarters in a row.
BPTH quarterly Sales and Income evolution
2017-Q4$0.04 M-$-2.17 M-5856.8%-

Bio-Path ownership

Checking Bio-Path ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Bio-Path, 1.26% of all outstanding shares are owned by its staff.

In case of Bio-Path stock, 11.43% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BPTH stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Bio-Path:

Market cap$18.5 M
Total shares3.7 M
Float shares3.7 M
  - Institutional holdings (%)11.4%
  - Insider holdings (%)1.3%
Shares in short selling0.0%

Bio-Path summary

Thursday, May 14th, 2020
Day range$4.69 - $5.10
Previous close$5.08
Session gain-1.18%
Average true range$0.40
50d mov avg$4.69
100d mov avg$5.80
200d mov avg$8.14
Daily patternlt03a
Weekly pattern lb01a

Bio-Path performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Bio-Path, the benchmark is made against .

Bio-Path competitors

Unfortunately, we could not find any public company that could be defined as Bio-Path competitor. This doesn't mean Bio-Path does not have any competitor in the market, it's just we could not detected it.